Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,857 papers from all fields of science
Search
Sign In
Create Free Account
Hemofil
Known as:
Hemofil HM
, Hemofil M
, Hemophil
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Factor VIII
factor VIII, human
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
G. Salvagno
,
J. Astermark
,
+5 authors
E. Berntorp
Haemophilia
2007
Corpus ID: 19595275
Summary. In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII…
Expand
2005
2005
Monoclate-P — Hemofil-M study
S. Seremetis
Annals of Hematology
2005
Corpus ID: 19272703
In the United States, at least 70% of patients with severe hemophilia A who were treated prior to 1984 with concentrates are HIV…
Expand
1992
1992
Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M)
M. Morfini
,
G. Longo
,
A. Messori
,
M. Lee
,
G. White
,
P. Mannucci
Thrombosis and Haemostasis
1992
Corpus ID: 43767094
Summary A recombinant FVIII preparation, Recombinate™, was compared with a high-purity plasma-derived concentrate, Hemofil® M, in…
Expand
1992
1992
Low recovery in vivo of highly purified factor VIII in patients with hemophilia.
C. Manno
,
R. Butler
,
A. Cohen
Jornal de Pediatria
1992
Corpus ID: 25934986
1991
1991
Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates.
M. Morfini
,
P. Mannucci
,
G. Longo
,
S. Cinotti
,
A. Messori
Thrombosis Research
1991
Corpus ID: 46455080
Review
1991
Review
1991
Ultrapure plasma factor VIII produced by anti-FVIIIc immunoaffinity chromatography and solvent/detergent viral inactivation. Characterization of the Method M process and Hemofil M antihemophilic…
M. Griffith
Annals of Hematology
1991
Corpus ID: 13138625
ConclusionsThe Method M process was developed to reduce the risk of virus transmission associated with the therapeutic use of AHF…
Expand
1991
1991
In Vivo Recovery and Survival of Monoclonal-Antibody-Purified Factor VIII Concentrates
C. Kasper
,
Hugh C. Kim
,
+5 authors
R. Montgomery
Thrombosis and Haemostasis
1991
Corpus ID: 45699901
Summary In response to reports of discrepant in vitro assays of high-purity concentrates, a double-blind crossover study of in…
Expand
Highly Cited
1985
Highly Cited
1985
Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.
W. Fricke
,
K. Brinkhous
,
J. Garris
,
H. Roberts
Blood
1985
Corpus ID: 904867
An acquired inhibitor of von Willebrand factor (vWF) activity occurring in a patient with benign gammopathy and von Willebrand…
Expand
1974
1974
Comparative chromatography of plasma and plasma concentrates rich in factors VIIIand IX.
R. Losito
,
E. Lemieux
,
B. Longpré
Journal of Chromatography A
1974
Corpus ID: 44521770
1972
1972
Factor VIII Concentrates in Outpatient Therapy
Charles M. Smith
,
G. Miller
,
R. Breckenridge
1972
Corpus ID: 71501538
Two factor VIII concentrates, Courtland and Hemofil, were evaluated during 64 courses of therapy in 26 classic hemophiliacs who…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE